AU2014273911B2 - Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor - Google Patents

Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor Download PDF

Info

Publication number
AU2014273911B2
AU2014273911B2 AU2014273911A AU2014273911A AU2014273911B2 AU 2014273911 B2 AU2014273911 B2 AU 2014273911B2 AU 2014273911 A AU2014273911 A AU 2014273911A AU 2014273911 A AU2014273911 A AU 2014273911A AU 2014273911 B2 AU2014273911 B2 AU 2014273911B2
Authority
AU
Australia
Prior art keywords
inhibitors
limited
incorporated
group
dianhydrogalactitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014273911A
Other languages
English (en)
Other versions
AU2014273911A1 (en
Inventor
Jeffrey BACHA
Dennis M. Brown
Howard A. Burris Iii
William Garner
Sareth KANEKAL
Richard Schwartz
Kent C. Shih
Anne STEINO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Del Mar Pharmaceuticals
Original Assignee
Del Mar Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Del Mar Pharmaceuticals filed Critical Del Mar Pharmaceuticals
Publication of AU2014273911A1 publication Critical patent/AU2014273911A1/en
Application granted granted Critical
Publication of AU2014273911B2 publication Critical patent/AU2014273911B2/en
Priority to AU2019283893A priority Critical patent/AU2019283893B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
AU2014273911A 2013-05-31 2014-06-02 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor Ceased AU2014273911B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019283893A AU2019283893B2 (en) 2013-05-31 2019-12-18 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829739P 2013-05-31 2013-05-31
US61/829,739 2013-05-31
PCT/US2014/040461 WO2014194312A2 (en) 2013-05-31 2014-06-02 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019283893A Division AU2019283893B2 (en) 2013-05-31 2019-12-18 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor

Publications (2)

Publication Number Publication Date
AU2014273911A1 AU2014273911A1 (en) 2016-01-07
AU2014273911B2 true AU2014273911B2 (en) 2019-09-19

Family

ID=51989551

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014273911A Ceased AU2014273911B2 (en) 2013-05-31 2014-06-02 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor
AU2019283893A Ceased AU2019283893B2 (en) 2013-05-31 2019-12-18 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019283893A Ceased AU2019283893B2 (en) 2013-05-31 2019-12-18 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor

Country Status (14)

Country Link
US (1) US11026914B2 (enExample)
EP (1) EP3003321A4 (enExample)
JP (3) JP2016520622A (enExample)
KR (4) KR20220080199A (enExample)
CN (1) CN105579044A (enExample)
AU (2) AU2014273911B2 (enExample)
BR (1) BR112015029989A2 (enExample)
CA (1) CA2914025C (enExample)
CL (1) CL2015003512A1 (enExample)
IL (1) IL242853B (enExample)
MX (1) MX382824B (enExample)
SG (1) SG11201509837QA (enExample)
TW (1) TW201536278A (enExample)
WO (1) WO2014194312A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014179528A2 (en) * 2013-05-01 2014-11-06 Brown Dennis M Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2016138542A1 (en) * 2015-02-28 2016-09-01 Cyprus Therapeutics, Inc. Methods for inhibiting tumors and drug resistance
US20190091195A1 (en) * 2015-09-10 2019-03-28 Del Mar Pharmaceuticals Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer
CA3010329A1 (en) * 2015-12-29 2017-07-06 Oncobiologics, Inc. Buffered formulations of bevacizumab
US20200062839A1 (en) * 2017-05-01 2020-02-27 Del Mar Pharmaceuticals (Bc) Ltd. Use of dianhydrogalactitol or analogs and derivatives in combination with vegf inhibitors to treat cancer
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
WO2018226939A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
EA202090024A1 (ru) 2017-06-12 2020-04-10 Станислав Р. Бурзинский Способы лечения лептоменингеального заболевания
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
WO2019211708A1 (en) * 2018-05-04 2019-11-07 Kashiv Biosciences, Llc Stable pharmaceutical compositions of dianhydrogalactitol
CN109337884B9 (zh) * 2018-12-21 2021-10-29 中国农业科学院北京畜牧兽医研究所 一种丙酮酸激酶基因及其应用
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
KR102415193B1 (ko) 2020-04-16 2022-06-29 사회복지법인 삼성생명공익재단 벤즈브로마론을 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학 조성물
US20230212571A1 (en) * 2020-06-08 2023-07-06 Neonc Technologies, Inc. Compositions and methods for delivering polynucleotides
CN114796522A (zh) * 2022-01-06 2022-07-29 宁波大学 一种靶向线粒体放大氧化应激的新型抗肿瘤纳米药物
WO2024039764A2 (en) * 2022-08-17 2024-02-22 Ohio State Innovation Foundation Epitranscriptomic analysis of glioma
KR20250052523A (ko) 2023-10-11 2025-04-21 서울대학교병원 재발성 뇌 종양 진단, 예방 또는 치료에서의 cxcr-4의 용도
CN122163582A (zh) * 2026-05-12 2026-06-09 中唯国际生命科技有限公司 卫矛醇在制备治疗甲状腺癌药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169600A1 (en) * 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785077A (en) 1986-05-05 1988-11-15 Scripps Clinic And Research Foundation Substantially pure cytotoxicity triggering factor
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5294430A (en) * 1988-09-12 1994-03-15 University Of Rochester Use of dithiocarbamates to treat myelosuppression
BR112013003671A2 (pt) * 2010-08-18 2017-01-10 Del Mar Pharmaceuticals composições e métodos para melhorar os benefícios terapêuticos de compostos químicos administyrados sub-otimamente incluindo hexitóis substituídos tais como dianidrogalactitol e diacetildianidrogalactiol
CN115778934A (zh) * 2012-01-20 2023-03-14 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169600A1 (en) * 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BACHA, J., "DelMar Pharmaceuticals.", 14TH ANNUAL HEALTHCARE CONFERENCE., (2012-09-11) *
EAGAN R T ET AL, "Dianhydrogalactitol and radiation therapy. Treatment of supratentorial glioma", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, (1979-05-11), vol. 241, no. 19, pages 2046 - 2050 *
ESPANA P ET AL, "PHASE 2 STUDY OF DIANHYDROGALACTITOL IN MALIGNANT GLIOMA", CANCER TREATMENT REPORTS, US GOV. PRINT. OFF, US, (1978-08-01), vol. 62, no. 8, ISSN 0361-5960, pages 1199 - 1200 *
HU ET AL., "Abstract 811: VAL083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme.", CANCER RESEARCH, (2012), vol. 72, no. 8 *

Also Published As

Publication number Publication date
JP2022088616A (ja) 2022-06-14
SG11201509837QA (en) 2015-12-30
AU2014273911A1 (en) 2016-01-07
JP2020079259A (ja) 2020-05-28
KR20210100754A (ko) 2021-08-17
KR20220080199A (ko) 2022-06-14
EP3003321A4 (en) 2017-01-18
AU2019283893A1 (en) 2020-01-23
KR20160065776A (ko) 2016-06-09
WO2014194312A3 (en) 2015-02-05
KR20230124765A (ko) 2023-08-25
US20160158186A1 (en) 2016-06-09
BR112015029989A2 (pt) 2017-08-22
WO2014194312A2 (en) 2014-12-04
CA2914025C (en) 2023-03-07
US11026914B2 (en) 2021-06-08
AU2019283893B2 (en) 2022-03-24
CA2914025A1 (en) 2014-12-04
MX2015016404A (es) 2016-09-28
JP2016520622A (ja) 2016-07-14
MX382824B (es) 2025-03-13
TW201536278A (zh) 2015-10-01
CL2015003512A1 (es) 2016-09-09
EP3003321A2 (en) 2016-04-13
CN105579044A (zh) 2016-05-11
IL242853B (en) 2022-03-01

Similar Documents

Publication Publication Date Title
AU2019283893B2 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
US12336993B2 (en) Therapeutic benefit of suboptimally administered chemical compounds
US20210251944A1 (en) Methods for treating a cancer resistant to at least one tyrosine kinase inhibitor
US20150087687A1 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN110711188A (zh) 经取代的己糖醇类用于治疗恶性肿瘤的用途
AU2024200718A1 (en) Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
HK1224581A1 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired